CORDIS
EU research results

CORDIS

English EN

Synaptic mechanisms of memory loss: novel cell adhesion molecules as therapeutic targets

Objective

Memory loss is a central symptom in different diseases, and represents a significant social and economic burden for a large percentage of European citizens. The molecular and neurobiological bases of memory deficits are largely unknown and there are currently no drugs available that can markedly decelerate or prevent memory decline. To address this major problem, this project will investigate the role of novel synaptic cell adhesion molecules (CAMs) in memory loss, and the therapeutic value of targeting these CAMs to restore memory function and associated neurobiological mechanisms at the synaptic level. The selection of novel synaptic CAMs is based on (1) recent evidence showing that they can recruit the synaptic machinery and form synapses; (2) the implication of CAMs, in general, in synaptic plasticity and memory, and (3) a direct link established between synaptic remodelling and memory formation. We have assembled a multidisciplinary consortium including excellent European researchers in this field, covering a wide range of structural, biochemical, electrophysiological and behavioural expertise. To understand memory loss, three domains have been selected as among the most prominent and widespread disease domains affecting memory and quality of life in our society: psychiatric disorders, the neurodegenerative disorder of Alzheimer's disease, stress and aging. For each disease domain, specific and validated animal models will be used to investigate memory loss on molecular, subcellular, cellular and functional levels. Our approach will result in the preclinical development and validation of mimetic peptides for novel synaptic CAMs as potential drug candidates to treat memory deficits or prevent memory decline. The current proposal offers the groundbreaking possibility to raise the bar in memory research by targeting novel molecules and developing effective drugs to treat memory disturbances based on their biological mechanism.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE

Address

Batiment Ce 3316 Station 1
1015 Lausanne

Switzerland

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 574 636,40

Administrative Contact

Carmen Sandi (Prof.)

Participants (8)

Sort alphabetically

Sort by EU Contribution

Expand all

ENKAM PHARMACEUTICALS A/S

Denmark

EU Contribution

€ 250 000

KATHOLIEKE UNIVERSITEIT LEUVEN

Belgium

EU Contribution

€ 219 363

MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV

Germany

EU Contribution

€ 428 722

AGENCIA ESTATAL CONSEJO SUPERIOR DEINVESTIGACIONES CIENTIFICAS

Spain

EU Contribution

€ 375 350

THE OPEN UNIVERSITY

United Kingdom

EU Contribution

€ 452 960

INSTYTUT BIOLOGII DOSWIADCZALNEJ IM. M. NENCKIEGO POLSKIEJ AKADEMII NAUK

Poland

EU Contribution

€ 290 600

SCIPROM SARL

Switzerland

EU Contribution

€ 124 200

NEOLOCH PHARMACEUTICALS APS

Denmark

EU Contribution

€ 254 540,60

Project information

Grant agreement ID: 201600

Status

Closed project

  • Start date

    1 February 2008

  • End date

    30 April 2011

Funded under:

FP7-HEALTH

  • Overall budget:

    € 4 138 676,19

  • EU contribution

    € 2 970 372

Coordinated by:

ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE

Switzerland